Actinium-225 Therapeutic Radioisotope - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The actinium-225 therapeutic radioisotope market size was valued at USD 261.21 million in 2025 and is estimated to grow from USD 298.55 million in 2026 to reach USD 582.35 million by 2031, at a CAGR of 14.30% during the forecast period (2026-2031). This report is Segmented by Production Method (Thorium-229 Decay, Cyclotron, Reactor/Accelerator Hybrid, Others), Application (Prostate Cancer, Neuroendocrine Tumors, Leukemia, Pancreatic Cancer, R&D, Others), End User (Hospitals, Academic Institutes, Pharma/Biotech, Radiopharmacies, Others), and Geography (North America, Europe, Asia-Pacific, and More). Forecasts are in Value (USD).

Global Actinium-225 Therapeutic Radioisotope Market Trends and Insights

Rising Clinical Adoption in Targeted Alpha Therapy Oncology

The actinium-225 therapeutic radioisotope market is benefiting from stronger clinical confidence in targeted alpha therapy, especially in prostate cancer programs that now report meaningful response activity with better-managed toxicity profiles. Phase 1 findings from Bayer’s PAnTHa study, presented at the 2026 ASCO Genitourinary Cancers Symposium, showed PSA50 responses in 83% of patients at the recommended expansion dose of 125 kBq/kg, and the study also reported no grade 3 or 4 salivary toxicities at that dose level. A 2026 clinical landscape review from Nucleus RadioPharma identified 28 active Phase I and Phase I/II alpha therapy trials worldwide, with actinium-225 programs accounting for a large share of that early development base. The clinical role of actinium-225 is also broadening because published reviews show activity in patients who are refractory to lutetium-177 PSMA therapy, which means the actinium-225 therapeutic radioisotope market can grow alongside lutetium-177 rather than only against it. Regulatory support is also reinforcing demand expansion, as the FDA granted Fast Track designation to Aktis Oncology’s AKY-1189 in January 2026 for urothelial cancer, extending visible pipeline interest beyond prostate cancer and supporting broader clinical use cases for the actinium-225 therapeutic radioisotope market.

Expansion of Late-Stage Radiopharmaceutical Pipelines

The actinium-225 therapeutic radioisotope market is being supported by a visible move from exploratory work into later-stage radiopharmaceutical programs, and that shift raises isotope demand per study as patient cohorts expand. AstraZeneca’s Phase 2 study of FPI-2265 in PSMA-positive metastatic castration-resistant prostate cancer is already positioned as a registration-enabling program for patients who previously received lutetium-177 PSMA therapy, which shows that development activity is no longer limited to early proof-of-concept work. In March 2026, the FDA cleared the IND for Aktis Oncology’s [225Ac]Ac-AKY-2519 to move into Phase 1b trials across prostate, lung, and other solid tumors, which widened the tumor mix under active evaluation. As more programs move toward larger and more complex study designs, isotope procurement becomes part of development planning much earlier than before, and that changes how companies sequence their clinical operations within the actinium-225 therapeutic radioisotope market. The practical result is a faster connection between pipeline maturity and supply planning, which keeps the actinium-225 therapeutic radioisotope market closely tied to execution speed in radiopharmaceutical development.

Persistent Global Supply Bottlenecks

Supply remains the clearest operational restraint on the actinium-225 therapeutic radioisotope market because the installed production base is still small relative to the number of clinical and pre-commercial programs that are already moving forward. The current supply structure still leans heavily on legacy thorium-229 resources, while alternative production routes are only now moving into more dependable commercial or near-commercial operation. Large capacity additions are underway, but several of the most important projects are still being built or scaled, which means the actinium-225 therapeutic radioisotope market is likely to remain tight until those facilities begin contributing at a meaningful level. This also creates a practical imbalance between developers with secured access and developers that still depend on spot or short-notice material availability, and that imbalance slows broader participation in the actinium-225 therapeutic radioisotope market. Until more distributed output becomes routine, supply tightness will continue to influence study pacing, commercial readiness, and the bargaining position of established producers.

Other drivers and restraints analyzed in the detailed report include:

• Long-Term Supply Agreements Reducing Procurement Uncertainty
• Government Funding for Isotope Production Infrastructure
• High Regulatory Burden Across Nuclear And Drug Authorities

Segment Analysis

Thorium-229 decay-based production held 55.31% of the actinium-225 therapeutic radioisotope market size in 2025, reflecting its long-standing role as the most established and most clinically familiar source of actinium-225. This route continues to benefit from a history of use and a high level of confidence around output quality, which explains why it remains the reference point for supply discussions across the actinium-225 therapeutic radioisotope market. At the same time, the method is tied to a finite feedstock base, and that creates a natural ceiling that cannot fully match the long-term needs of expanding radiopharmaceutical programs. That ceiling is one reason producers, governments, and research centers are putting more effort into scalable alternatives that can distribute production risk more widely across the actinium-225 therapeutic radioisotope market.

Cyclotron-based production is forecast to grow at 17.38% CAGR through 2031, making it the fastest-growing production route as suppliers move toward larger and more repeatable output. Eckert and Ziegler and the Nuclear Physics Institute of the Czech Academy of Sciences transitioned their joint initiative into high-volume cyclotron production in February 2026, which marked a practical step from development work into a more industrial supply model. NorthStar also confirmed successful routine commercial-scale actinium-225 production in January 2026 and later secured FDA acceptance of its Drug Master File for no-carrier-added actinium-225, adding another credible route to commercial supply. Hybrid and accelerator-linked approaches are also gaining relevance, with the DOE tri-lab effort and the first FDA-approved clinical trial using exclusively accelerator-produced actinium-225 helping reduce the earlier hesitation around non-generator supply. The overall mix is therefore shifting from dependence on one dominant route toward a broader supply base, which makes the actinium-225 therapeutic radioisotope market less exposed to a single feedstock or facility network.

Complete Report Scope:

• By Production Method
  • Thorium-229 Decay-Based Production
  • Cyclotron-Based Production
  • Reactor and Accelerator Hybrid Production
  • Other Production Methods
• By Application
  • Prostate Cancer
  • Neuroendocrine Tumors
  • Leukemia
  • Pancreatic Cancer
  • Research and Development
  • Other Applications
• By End User
  • Hospitals and Cancer Centers
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Radiopharmacies
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America captured 36.22% of the actinium-225 therapeutic radioisotope market size in 2025, supported by long-established isotope infrastructure, national laboratory capabilities, and a dense base of radiopharmaceutical developers and suppliers. The United States remains central to this position because the Department of Energy continues to fund isotope expansion, including actinium-225 scale-up work at Brookhaven National Laboratory. The region is also adding future capacity through TerraPower Isotopes’ Bellwether Laboratory in Philadelphia, a USD 450 million project designed to increase production capacity 20-fold by 2029. Canada adds depth through production activity connected to TRIUMF and through targeted funding for cyclotron-linked expansion, which helps preserve North America’s lead in the actinium-225 therapeutic radioisotope market.

Europe remains the second-largest regional base in the actinium-225 therapeutic radioisotope market, with strength in both production capability and clinical use. Germany has an important position because it combines supplier activity with clinical treatment expertise, while the Czech Republic supports the region’s emerging cross-border production cluster. In February 2026, Eckert and Ziegler and UJF increased production volume through their joint actinium-225 initiative, giving Europe a more visible industrial supply role. The European Commission’s Joint Research Centre is also developing a liquid radium-226 target method that supports radium recycling, improved yield economics, and lower waste burden, which strengthens the region’s technical diversity inside the actinium-225 therapeutic radioisotope market.

Asia-Pacific is the fastest-growing regional segment at 20.15% CAGR through 2031, which gives the actinium-225 therapeutic radioisotope market its strongest growth runway outside North America. Japan leads this regional acceleration through an explicit domestic manufacturing push. The Quantum Science and Technology Research and Development Organization began supplying actinium-225 to the National Cancer Center Research Institute in March 2025 under a cooperation framework signed in December 2024, showing that the region is moving from planning into operating supply relationships. Japan is also targeting an actinium-225 production demonstration in the fast reactor Joyo by FY2026, while NovAccel plans to begin sample supply from Hiroshima University in Q4 2026 using its compact superconducting accelerator platform. The Middle East and Africa remain early-stage participants, though South Africa’s role in the IAEA Global Radium-226 Management Initiative shows that feedstock and capability building are already underway. South America is still nascent in the actinium-225 therapeutic radioisotope market, but it remains strategically relevant because any future regional growth will depend on whether local nuclear medicine systems can connect with international isotope supply and therapy delivery standards.

List of Companies Covered in this Report:

• Actinium Pharmaceuticals, Inc.
• AdvanCell Pty Ltd.
• AstraZeneca
• Bayer Aktiengesellschaft
• BWXT Medical Ltd.
• Cellectar Biosciences, Inc.
• Curium Pharma
• Eckert and Ziegler Strahlen- und Medizintechnik AG
• Eli Lilly and Company
• Fusion Pharmaceuticals Inc.
• ITM Isotope Technologies Munich SE
• Lantheus Holdings, Inc.
• Niowave, Inc.
• NorthStar Medical Radioisotopes, LLC
• PanTera
• RadioMedix, Inc.
• RayzeBio, Inc.
• Telix Pharmaceuticals Limited
• TerraPower Isotopes, LLC

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support